NLA Nasal Spray - Meda

Drug Profile

NLA Nasal Spray - Meda

Alternative Names: NCX-1510; Nitric oxide-releasing cetirizine liposomal - Orexo; NLA; NO-releasing cetirizine liposomal - Orexo; OX-NLA

Latest Information Update: 03 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NicOx
  • Developer Meda
  • Class Acetic acids; Antiallergics; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 09 Mar 2012 Clinical development is ongoing in Sweden
  • 14 Apr 2008 Orexo's cetirizine-based nasal spray licensed worldwide to Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top